Midatech Pharma Plc (MTPH):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Midatech Pharma Plc (MTPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8130)・商品コード:DATA904C8130
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:77
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The company’s products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimmune diseases, pipeline, Q-octreotide, opsisporin, HCC, glioblastoma and diabetes vaccine. Midatech’s products are used in treatment of diabetes; rare cancers including brain, ovarian, liver and pancreatic cancer and neurological and ophthalmologic conditions. It collaborates with universities, and specialty and major pharmaceutical companies to develop its platform technologies. The company operates through its manufacturing facility in Bilbao, and research facility in Cardiff. Midatech is headquartered in Abingdon, the UK.

Midatech Pharma Plc (MTPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 14
Venture Financing 15
Q Chip Raises US$3 Million Venture Financing 15
Private Equity 16
Kanwa Holdings to Acquire Midatech Pharma US from Midatech Pharma 16
Partnerships 18
Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 18
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 19
Midatech Pharma Enters into Agreement with Ophthotech 20
Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 21
DARA BioSciences Enters into Commercialization Agreement with Onxeo 22
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 23
Midatech Enters into Research Collaboration Agreement with Middlesex University 24
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 25
Midatech Enters into Research and Collaboration Agreement with The Open University 26
Midatech Enters Into Joint Venture With MonoSol Rx 27
Licensing Agreements 28
Midatech Pharma Enters Into Licensing Agreement with Novartis 28
Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 29
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 30
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 31
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 32
Equity Offering 33
Midatech Pharma Raises USD8 Million in Private Placement of Shares 33
Midatech Pharma to Raise USD2.7 Million in Rights Offering of Shares 34
Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 35
Midatech Pharma Raises USD50 Million in IPO 36
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 38
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 39
Dara BioSciences Raises USD6 Million in Private Placement Of Shares 40
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 41
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 42
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 43
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 44
DARA BioSciences Completes Public Offering Of Units For US$10 Million 45
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 47
Acquisition 49
Midatech Pharma Acquires Dara BioSciences 49
Midatech Pharma Acquires Q Chip 51
DARA BioSciences Acquires Oncogenerix 52
Midatech Pharma Plc – Key Competitors 53
Midatech Pharma Plc – Key Employees 54
Midatech Pharma Plc – Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Joint Venture 55
Recent Developments 56
Strategy And Business Planning 56
Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility 56
Financial Announcements 57
Apr 23, 2018: Midatech Pharma: Audited financial results for the year ended 31 December 2017 57
Sep 28, 2017: Midatech Pharma: Interim results for the six months ended 30 June 2017 63
Apr 04, 2017: Midatech Pharma Announces Audited financial results for the year ended 31 December 2016 67
Jan 20, 2017: Midatech Pharma Provides Trading Update 68
Corporate Communications 69
Jun 01, 2018: Midatech Pharma: Board change 69
Mar 15, 2018: Midatech announces changes in Senior Management Team 70
Government and Public Interest 71
Nov 23, 2017: Midatech secures manufacturing certification from Spanish regulatory authority 71
Product News 72
May 22, 2017: Midatech announces progress update on brain cancer therapies 72
01/16/2018: Midatech and UCSF receive IND approval for DIPG treatment MTX110 73
Clinical Trials 74
May 25, 2018: Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer 74
Jul 26, 2017: Midatech Pharma: Completion of pre-clinical liver cancer programme 75
Other Significant Developments 76
Jul 25, 2018: Midatech Pharma: Trading update 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Midatech Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Midatech Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 14
Q Chip Raises US$3 Million Venture Financing 15
Kanwa Holdings to Acquire Midatech Pharma US from Midatech Pharma 16
Midatech Pharma US Enters into Co-Promotion Agreement with Bausch Health 18
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 19
Midatech Pharma Enters into Agreement with Ophthotech 20
Midatech Pharma Enters into Agreement with Dana-Farber Cancer Institute 21
DARA BioSciences Enters into Commercialization Agreement with Onxeo 22
DARA BioSciences Enters into Co-Promotion Agreement with Mission Pharmacal 23
Midatech Enters into Research Collaboration Agreement with Middlesex University 24
Dara BioSciences Enters Into Agreement With T3D Therapeutics For DB959 25
Midatech Enters into Research and Collaboration Agreement with The Open University 26
Midatech Enters Into Joint Venture With MonoSol Rx 27
Midatech Pharma Enters Into Licensing Agreement with Novartis 28
Emergex Vaccines Enters into Licensing Agreement with Midatech Pharma 29
Helsinn Enters Into Licensing Agreement With Dara BioSciences For Gelclair 30
DARA BioSciences Enters Into Licensing Agreement With Innocutis For Bionect 31
DARA BioSciences Enters Into Licensing Agreement With Uman Pharma For Gemcitabine 32
Midatech Pharma Raises USD8 Million in Private Placement of Shares 33
Midatech Pharma to Raise USD2.7 Million in Rights Offering of Shares 34
Midatech Pharma Raises USD19.8 Million in Private Placement of Shares 35
Midatech Pharma Raises USD50 Million in IPO 36
Dara BioSciences Raises USD12.5 Million in Public Offering of Units 38
Dara BioSciences Files Registration Statement For Public Offering Of Units For Up To US$32.5 Million 39
Dara BioSciences Raises USD6 Million in Private Placement Of Shares 40
Dara BioSciences Completes Private Placement Of Shares For US$2.6 Million 41
Dara BioSciences Announces Public Offering Of Common Stock For US$2.7 Million 42
Dara BioSciences Completes Private Placement Of Series B-3 Preferred Stock For US$2.6 Million 43
Dara BioSciences Completes Private Placement Of Series B-4 Preferred Stock For US$0.3 Million 44
DARA BioSciences Completes Public Offering Of Units For US$10 Million 45
DARA BioSciences Completes Private Placement Of Preferred Stock For US$1.7 Million 47
Midatech Pharma Acquires Dara BioSciences 49
Midatech Pharma Acquires Q Chip 51
DARA BioSciences Acquires Oncogenerix 52
Midatech Pharma Plc, Key Competitors 53
Midatech Pharma Plc, Key Employees 54
Midatech Pharma Plc, Subsidiaries 55
Midatech Pharma Plc, Joint Venture 55

List of Figures
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Midatech Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Midatech Pharma Plc, Medical Devices Deals, 2012 to YTD 2018 11

★調査レポート[Midatech Pharma Plc (MTPH):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8130)販売に関する免責事項を必ずご確認ください。
★調査レポート[Midatech Pharma Plc (MTPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆